Home

  • EULAR 2026: Do Not Miss- Artificial Intelligence

    Piotr Kuszmiersz

    x

    Poster 0317 | Friday 13.06.25 09:30 AM
    Clinical Poster Tours: Systemic lupus erythematosus II
    Author: Andrea Fava (USA)
    Title: The immune map of lupus nephritis: a spatially-resolved kidney proteomic approach
     
    This study developed an innovative 18-plex serial immunohistochemistry workflow to map the spatial organization of immune cells in lupus nephritis kidney biopsies.
    Using advanced AI-assisted analysis on 29 kidney biopsies containing nearly 2 million cells, researchers identified over 12,000 cellular aggregates and discovered distinct immune cell structures in different kidney regions.The findings revealed that while most aggregates were small, medium and large aggregates contained one-third of all immune cells and showed different compositions related to disease severity. Glomerular aggregates were primarily composed of myeloid cells and associated with protein levels, while tubulointerstitial aggregates showed greater diversity and correlated with kidney function. This spatial mapping approach provides new insights into lupus nephritis pathogenesis and potential therapeutic targets.
    ,
    , ,

  • EULAR 2026: Do Not Miss- Vasculitis and other Connective Tissue Diseases

    Andreu Fernandez-Codina
    X

    Poster 0329 | Friday, 13th June 2025 09:30 CEST
    Clinical Poster Tours: Treatment aspects of small vessels vasculitis and Behcet’s disease
    Author: M. Shiomi (Japan)
    Title: Recent glucocorticoid-sparing strategies lead to better prognosis for ANCA-associated vasculitis: Insights from the multicenter REVEAL cohort study

    A real-world multicenter study of 460 AAV patients from the REVEAL cohort found that recent glucocorticoid-sparing strategies, increasingly adopted after 2019, were associated with improved prognosis. Although MPA showed the highest mortality, reduced glucocorticoid exposure correlated with better survival outcomes across all AAV subtypes.

    ,
    , ,

  • EULAR 2026: Do Not Miss – Rare and Autoinflammatory diseases

    Alessandro Tomelleri
    X

    Poster POS0381 | Saturday 14.06.2025 10:30 AM
    Poster Tour II
    Author: Byram, K (Czech Republic)
    Title: Development of a disease activity index for the assessment of VEXAS syndrome (VEXAS-DAI)

    This study presents the development of the VEXAS Disease Activity Index (VEXAS-DAI), a consensus-based tool encompassing 12 clinical domains to quantify inflammation severity in VEXAS syndrome. Created via Delphi methodology and expert input, the VEXAS-DAI aims to standardize disease activity assessment and will undergo validation in upcoming clinical trials.
    ,
    , ,

  • EULAR 2026: Do Not Miss -Osteoarthritis and Osteoporosis

    Victoria Sadovici


    X

    Poster 0565 | Wednesday 11.06.25 15:30-16:30 PM
    Session: Poster View I
    Author: B. van den Bemt (Netherlands)
    Title: Overview of authorised drugs to be repurposed for the treatment of osteoarthritis: a scoping review of clinical studies
     
    This scoping review maps all clinical research (177 studies, 42+ drugs) repurposing authorized drugs for osteoarthritis (OA), where no disease-modifying treatments exist. It reveals predominantly short-term symptom focus with limited success, identifies promising long-term structure/outcome impacts, and catalogs 24 understudied candidates. This exhaustive landscape analysis is vital to strategically accelerate cost-effective DMOAD discovery.

    ,
    , ,

  • EULAR 2026: Do Not Miss- Basic and Translational Research I

    Bohdana Doskaliuk
    Bohdana is an Associate Professor at Ivano-Frankivsk National Medical University. Her PhD research focused on pulmonary involvement in systemic sclerosis and its potential correction.
    Bohdana actively contributes also as a reviewer and editor. She serves as an Associate Editor for Rheumatology International and is the Editorial Board member for Therapeutic Advances in Musculoskeletal Disease and Rheumatology Advances in Practice. She is also affiliated with the European Academy of Allergy and Clinical Immunology and European Respiratory Society. Bohdana is a Country Liaison Sub-Committee member.

    Oral OP0251 | Friday 13.06.2025 10.30
    Basic Abstract Sessions: Cutting the edges – Omics and new targets in SpA and other inflammatory arthritis
    Author:  Giaglis, S (Switzerland)
    Title: A cutting-edge three-dimensional stromal-immune microenvironment emulates interactions between synovial fibroblasts and macrophages in inflammatory arthropathies

    This study presents a novel 3D organoid model replicating the human synovial microenvironment using patient-derived fibroblasts and macrophages. The model mimics inflammation seen in arthritis and reveals key cytokine responses, offering insights into individual disease mechanisms. It holds promise for personalized therapy development and improves upon the predictive limitations of traditional 2D cultures and animal models.

    ,
    , ,

  • EULAR 2026: Do Not Miss- Basic and Translational Research II

    Nikolaos Vlachogiannis
    X

    Oral OP0023 | Wednesday 11.06.2025 5.30pm
    Basic Abstract Sessions: Understanding Basic and Translational Science in Vasculitis
    Author: M Sandovici (Netherlands)
    Title: Crosstalk between macrophages and fibroblasts likely contributes to inflammation and damage in giant cell arteritis

    This study provides evidence of crosstalk between macrophages and fibroblasts in GCA. Local production of GM-CSF and M-CSF by fibroblasts may contribute to tissue skewing of infiltrating monocytes towards CD206+ and FRβ+ macrophages. Conversely, particular macrophage subtypes may influence the phenotype of vascular fibroblasts in GCA.

    ,
    , ,

  • EULAR 2026: Do Not Miss- Spondyloarthritis I – non-therapeutic

    Miranda van Lunteren

    X

    Oral OP0098 | Wednesday 11.06.2025 4.40pm
    Clinical Abstract Sessions: Spondyloarthritis
    Author: F Proft (Germany)
    Title: Assessing the Frequency of Difficult-to-Manage (D2M) and Treatment-Refractory (TR-axSpA) Cases in the RABBIT-SpA Register: An Analysis Based on Recent ASAS Definitions
     
    In the German RABBIT-SpA cohort, 8.5% of b/tsDMARD-naïve axSpA patients met ASAS criteria for Difficult-to-Manage (D2M) axSpA, and 2.5% for Treatment-Refractory (TR) axSpA. D2M patients were more often female, less frequently HLA-B27 positive, with greater peripheral involvement and worse patient-reported outcomes. TR patients showed persistent inflammation with elevated CRP and MRI findings. These criteria help identify patients with challenging disease courses early, potentially guiding tailored management strategies for those at risk of poor treatment response.
    ,
    , ,

  • EULAR 2026: Do Not Miss- Spondyloarthritis II – therapeutic

    Hannah den Braanker

    X

    Oral 0089 | Wednesday 11.06.25 16:30-16:40 PM
    Clinical Abstract Sessions: Shaping the Future of Psoriatic Arthritis Treatment
    Author: L.C. Coates (United Kingdom)
    Title: Early intensive therapy with combination csDMARDs or TNF inhibitors are superior to standard step-up care for the treatment of moderate-to-severe psoriatic arthritis: the 3-arm parallel group SPEED RCT
     
    The SPEED trial demonstrates that initial intensive therapy with early biologics or combination DMARDs provides superior disease control compared to standard step-up care in early moderate-severe psoriatic arthritis patients with poor prognostic factors. Benefits from early TNF inhibitor therapy persisted at one year, supporting a more aggressive initial treatment approach.
    ,
    , ,

  • EULAR 2026: Do Not Miss- Rheumatoid Arthritis

    Álvaro Gómez

    X

    Oral OP0066 | Wednesday 11.06.2025 4.40pm
    Co-morbidities in Rheumatoid Arthritis – Cancer and cardiovascular events
    Author: R Westermann (Denmark)
    Title: The risk of cancer recurrence with bDMARD treatment in patients with rheumatoid arthritis and a history of cancer: a nationwide Danish register-based cohort study

    In this nationwide observational cohort study of Danish rheumatoid arthritis patients with a solid cancer in remission (2002 to 2021), treatment with bDMARDs (TNF inhibitors, IL-6 inhibitors, rituximab and abatacept) was not found to be associated with increased risks of cancer recurrence compared with csDMARD treatment.

    ,
    , ,

  • EULAR 2026: Do Not Miss- SLE &  APS

    Daliya Pencheva

    x

    Poster 0317 | Friday 13.06.25 09:30 AM
    Clinical Poster Tours: Systemic lupus erythematosus II
    Author: Andrea Fava (USA)
    Title: The immune map of lupus nephritis: a spatially-resolved kidney proteomic approach
     
    This study developed an innovative 18-plex serial immunohistochemistry workflow to map the spatial organization of immune cells in lupus nephritis kidney biopsies.
    Using advanced AI-assisted analysis on 29 kidney biopsies containing nearly 2 million cells, researchers identified over 12,000 cellular aggregates and discovered distinct immune cell structures in different kidney regions.The findings revealed that while most aggregates were small, medium and large aggregates contained one-third of all immune cells and showed different compositions related to disease severity. Glomerular aggregates were primarily composed of myeloid cells and associated with protein levels, while tubulointerstitial aggregates showed greater diversity and correlated with kidney function. This spatial mapping approach provides new insights into lupus nephritis pathogenesis and potential therapeutic targets.
    ,
    , ,